Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · GH Secretagogue

Hexarelin vs Tesamorelin

Hexarelin and Tesamorelin target different receptors entirely. Hexarelin is a potent ghrelin-receptor agonist (GHS-R1a). Tesamorelin is an FDA-approved GHRH analog. They are often compared because both aim at GH elevation but from opposite sides of the pulse-generating system.

Bangkok research desk ·

Side-by-side

Hexarelin Tesamorelin
MechanismPotent ghrelin-receptor agonist.44-amino-acid GHRH analog; FDA-approved.
Half-lifeShort.Short plasma; pulsatile output.
Dose100 mcg × 2-3 daily SC.1-2 mg daily SC (evening).
Cycle4-8 weeks.12 weeks on / 4 off (research); continuous clinical use.
Research contextAcute GH release; cortisol/prolactin elevation1.FDA-approved for HIV visceral adiposity; strong clinical endpoints2.
Cost tierLow-to-mid.High.

Hexarelin and Tesamorelin elevate GH through separate pathways. Hexarelin activates the ghrelin receptor and drives an acute pulse1. Tesamorelin activates the GHRH receptor and works with endogenous pituitary pulsatility, which is why its pharmacokinetic profile preserves the natural pulse pattern. The shared endpoint (elevated GH and IGF-1) masks two different mechanisms with different research implications.

Clinical registration is the clearest differentiator. Tesamorelin is FDA-approved for HIV-associated visceral adiposity with Phase 3 data on visceral fat reduction and liver fat reduction2. Hexarelin is a research compound with older human data focused on pituitary function and acute GH-release capacity, including in elderly populations.

Research protocols select Tesamorelin when the endpoint is metabolic, when comparator-grade clinical data matters, or when daily subcutaneous dosing is acceptable. They select Hexarelin when the endpoint is acute pituitary responsiveness, when cost per dose matters more than clinical rigour, or when the protocol is shorter than 8 weeks. The two are rarely stacked because both drive GH release directly; the standard cross-mechanism stack uses a cleaner GHS (Ipamorelin) with a GHRH analog (CJC-1295 or Tesamorelin). See Tesamorelin clinical history for the full Tesamorelin trial record.

Frequently asked

Are Hexarelin and Tesamorelin interchangeable?
No. They act on different receptors. Hexarelin is a ghrelin-receptor agonist; Tesamorelin is a GHRH analog. The downstream effect (elevated GH) is similar, but the pharmacology, dosing, and clinical-evidence base are different.
Why is Tesamorelin so much more expensive?
Tesamorelin is an FDA-approved therapeutic with patent protection and clinical-grade manufacturing requirements. Research-grade Tesamorelin sits above research-grade Hexarelin on per-cycle cost because of those upstream factors.
Can both be cycled together?
The literature does not standardly combine them because both drive GH release directly. The canonical stack crosses mechanisms: a GHS (Ipamorelin) with a GHRH analog (CJC-1295 or Tesamorelin).
Research desk
Ordering both Hexarelin and Tesamorelin for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Ghigo E, et al. Growth hormone-releasing activity of hexarelin. J Clin Endocrinol Metab. 1994. PMID: 8126144
  2. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PMID: 18057338

All references verified against PubMed via NCBI E-utilities.